UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 27, 2017
TRACON Pharmaceuticals, Inc. |
(Exact name of registrant as specified in its charter) |
Delaware |
| 001-36818 |
| 34-2037594 |
(State or other jurisdiction |
| (Commission File Number) |
| (IRS Employer Identification No.) |
of incorporation) |
|
|
|
|
8910 University Center Lane, Suite 700 San Diego, California |
| 92122 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (858) 550-0780
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
We are providing in Exhibit 99.1, which is incorporated herein by reference, certain disclosures required by Part III of our Annual Report on Form 10-K for the year ended December 31, 2016.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. |
| Description |
|
|
|
99.1 |
| Form 10-K, Part III Disclosures |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| TRACON Pharmaceuticals, Inc. | ||
|
|
| ||
Dated: March 27, 2017 |
|
|
|
|
|
| By: |
| /s/ Charles P. Theuer, M.D., Ph.D. |
|
|
|
| Charles P. Theuer, M.D., Ph.D. |
|
|
|
| President and Chief Executive Officer |